Annual report pursuant to Section 13 and 15(d)

Intangibles, net (Tables)

v3.21.1
Intangibles, net (Tables)
12 Months Ended
Dec. 31, 2020
Intangibles, net  
Schedule of JMC Intangible Asset

The table below provides a summary of intangible assets as of December 31, 2020 and 2019, respectively:

Estimated Useful

($ in thousands)

    

Lives (Years)

    

December 31, 2020

    

December 31, 2019

Total Intangible assets – asset purchases

3 to 7

$

18,606

$

9,934

Accumulated amortization

 

  

 

(3,977)

 

(2,557)

Net intangible assets

 

  

$

14,629

$

7,377

Schedule of JMC recognized expense related to its product licenses

The table below provides a summary for the years ended December 31, 2020 and 2019, of recognized expense related to  product licenses, which was recorded in costs of goods sold on the Consolidated Statement of Operations (see Note 19):

Intangible

($ in thousands)

    

Assets, Net

Beginning balance at December 31, 2018

$

1,417

Additions:

Purchase of Ximino1

7,134

Amortization expense

(1,174)

Beginning balance at December 31, 2019

7,377

Additions:

Isotretinoin Agreement2

4,727

Anti-itch product license acquisition3

3,945

Amortization expense

 

(1,420)

Ending balance at December 31, 2020

$

14,629

Note 1: Includes an upfront payment of $2.4 million and four payments totaling $7.0 million due in consecutive years commencing on the second anniversary of the execution of the APA. Such payments were discounted by $2.3 million as a result of the long-term nature of such payments.

Note 2: Includes an upfront payment of $1.0 million and a milestone payment of $0.5 million in 2020 and three payments totaling $3.5 million due at various points between 2021 through 2023. Such payments were discounted by $0.3 million as a result of the long-term nature of such payments. As of December 31, 2020, this asset has not yet been placed in service, therefore no amortization expense was recognized on this asset for the year ended December 31, 2020.  Journey expects the asset to be placed in service in the first half of 2021. Once the asset is placed in service Journey will amortize the asset over five years, which represents its expected useful life.

Note 3: Includes an upfront payment of $0.2 million and three payments totaling $2.8 million in 2021 and $1.0 million in 2022. Such payments were discounted by $0.1 million as a result of the long-term nature of such payments. As of December 31, 2020, this asset has not yet been placed in service, therefore no amortization expense was recognized on this asset for the year ended December 31, 2020. The Company expects to launch  this asset in Q3 2021. Once the asset is placed in service Journey will amortize the asset over three years, which represents its expected useful life.

Schedule of future amortization of intangible assets

The future amortization of these intangible assets is as follows:

Total

($ in thousands)

    

Ximino®

    

Exelderm®

    

Amortization

Year Ended December 31, 2021

$

1,019

$

267

$

1,286

Year Ended December 31, 2022

 

1,019

 

 

1,019

Year Ended December 31, 2023

1,019

1,019

Year Ended December 31, 2024

1,019

1,019

Year Ended December 31, 2025

 

1,019

 

 

1,019

Thereafter

595

595

Sub-total

5,690

267

5,957

Intangible assets not yet placed in service

8,672

Total

$

5,690

$

267

$

14,629